Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TO-O-1001 in Glaucoma and Ocular Hypertension
NCT05456724Phase 2Active, not recruiting
- Sponsor
- TheratOcular Biotek
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TO-O-1001 in open-angle glaucoma (OAG), ocular hypertension, sponsored by TheratOcular Biotek. Started Aug 2022; status: active, not recruiting.
02
Drugs
TO-O-1001
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05456724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456724.